Birte Wistinghausen, MD
- ASSOCIATE PROFESSOR | Pediatrics
Specialties:Pediatrics, Pediatric Hematology-Oncology
Dr. Birte Wistinghausen is the Medical Director of the Division of Pediatric Hematology-Oncology, and Associate Professor of Hematology-Oncology at the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai.
Dr. Wistinghausen earned her medical degree at Christian-Albrecht Universitat Kiel in 1993. After a two-year postdoctoral fellowship in the laboratory of Dr. Margaret Karpatkin describing a novel mutation leading to factor IX deficiency she went on to complete an internship and a residency in Pediatrics at New York University Medical Center in New York. She completed her fellowship in pediatric hematology-oncology at New York University Medical Center and Bellevue Hospital and received her first faculty appointment at New York University Medical Center.
As Clinical Director of Pediatric Hematology and Oncology, Dr. Wistinghausen specializes in diagnosing and treating pediatric patients with leukemia, lymphoma, Langerhans cell histiocytosis and pediatric solid tumors as well as treating selected benign hematological problems of childhood such as ITP, hemophagocytic lymphohistiocytosis (HLH) and hematological complications of solid organ transplantation. Dr. Wistinghausen’s research interests focus on clinical and translational research in non-Hodgkin lymphoma and post-transplant lymphoproliferative disease (PTLD). She currently serves as the institutional principal investigator for the Children’s Oncology Group and is a member of the NHL committee of the Children’s Oncology Committee where she has been appointed to spearhead the clinical research for B-lymphoblastic lymphoma in childhood and to develop a new national clinical and translational research protocol for the treatment of post-transplant lymphoproliferative disease with cellular based therapies. Dr. Wistinghausen has published articles about factor XI deficiency, hematological complications of solid organ transplantation, HLH and PTLD.
Pediatric Hematology & Oncology
- Ewing Sarcoma
- Osteogenic sarcoma
- Pediatric brain tumors
- Post transplant lymphoproliferative disease (PTLD)
MD, Christian-Albrecht Universitat
Residency, Pediatrics, Bellevue Hospital Center
Fellowship, Pediatrics/Hemo/Onc., Bellevue Hospital Center
First Sydney Q. Cohlan Resident and Fellow Research Award
Wistinghausen B, Reischer A, Oddoux C, Ostrer H, Nardi M, Karpatkin M. Severe factor XI deficiency in an Arab family associated with a novel mutation in exon 11. Br J Haematol 1997 Dec; 99(3): 575-7.
Lee CK, Raz R, Gimeno R, Gertner R, Wistinghausen B, Takeshita K, De Pinho RA, Levy DE. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity 2002 Jul; 17(1): 63-72.
Ramaswami A, Rosen DJ, Chu J, Wistinghausen B, Arnon R. Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report. Journal of pediatric hematology/oncology 2016 Jul;.